Research Funded by Box Rallies

Featured Research

Dr Latham’s team is pursuing the preclinical assessment and development of a novel class of drugs that aim to prevent cancer relapse by inhibiting the growth of cells that have already metastasised.

Explore Research

Advanced pre-clinical evaluation of sphingosine kinase 1-targeting agents as a therapy for acute myeloid leukaemia

Advancing CAR-T cell therapy for extracranial solid paediatric cancers

NSW

Advancing Liquid Biopsy Testing: Harnessing Epigenetics for Early Detection of Residual and Recurrent Breast Cancer

NSW

A patient-derived discovery platform for companion biomarker development in prostate cancer

A targeted therapy to enhance treatment efficacy and neuroprotection in glioblastoma

NSW

CAPP3: a randomized dose finding non inferiority study of aspirin to prevent cancer in Lynch Syndrome

VIC

Creating the Next Generation in Radiotherapy Imaging with Carbon Nanotube Sources and Photon Counting Detectors

NSW

Defining the cellular determinants that drive dynamin inhibitor induced cell death and in vivo efficacy against glioblastoma

NSW

Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management

VIC

Defining the critical role of osteoclasts in multiple myeloma cell growth and activation in bone

NSW

Developing a clinic-ready nanomedicine for RNA therapy for pancreatic and lung cancers

NSW

Developing a new blood-based screening test for bowel cancer

NSW

Developing a new strategy to reduce the side effects of bladder cancer treatment

Developing a novel targeted therapy for treating chemotherapy-resistant leukaemia

NSW

Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer

NSW

Research Funded by Box Rallies

Featured Research

Advanced pre-clinical evaluation of sphingosine kinase 1-targeting agents as a therapy for acute myeloid leukaemia

Advancing CAR-T cell therapy for extracranial solid paediatric cancers

Advancing Liquid Biopsy Testing: Harnessing Epigenetics for Early Detection of Residual and Recurrent Breast Cancer

Advancing Telomerase Inhibitors as potential cancer therapeutics

A new targeted therapy for resistant HER2+ breast cancers

A new therapeutic opportunity for gastrointestinal cancers

A patient-derived discovery platform for companion biomarker development in prostate cancer

A targeted therapy to enhance treatment efficacy and neuroprotection in glioblastoma

CAPP3: a randomized dose finding non inferiority study of aspirin to prevent cancer in Lynch Syndrome

Creating the Next Generation in Radiotherapy Imaging with Carbon Nanotube Sources and Photon Counting Detectors

Defining the cellular determinants that drive dynamin inhibitor induced cell death and in vivo efficacy against glioblastoma

Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management

Defining the critical role of osteoclasts in multiple myeloma cell growth and activation in bone

Developing a clinic-ready nanomedicine for RNA therapy for pancreatic and lung cancers

Developing a new blood-based screening test for bowel cancer

Developing a new strategy to reduce the side effects of bladder cancer treatment

Developing a novel targeted therapy for treating chemotherapy-resistant leukaemia

Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer